Evidence map›Paper›PMID 35335918›Full record

ArticlePharmaceutics2022

Sparsomycin Exhibits Potent Antiplasmodial Activity In Vitro and In Vivo.

Nanang Rudianto Ariefta, Baldorj Pagmadulam, Coh-Ichi Nihei, Yoshifumi Nishikawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Nanang Rudianto ArieftaNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro 080-8555, Japan.ORCID 0000-0002-3012-6005
Baldorj PagmadulamNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro 080-8555, Japan.
Coh-Ichi NiheiInstitute of Microbial Chemistry (BIKAKEN), 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.
Yoshifumi NishikawaNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro 080-8555, Japan.ORCID 0000-0001-5005-6377
Obihiro University of Agriculture and Veterinary Medicine · JPMicrobial Chemistry Research Foundation · JPMongolian Academy of Sciences · MN

Funding

Japan Society for the Promotion of Science 20F20402Japan Society for the Promotion of Science 26670204Obihiro University of Agriculture and Veterinary Medicine 2020-joint-14Obihiro University of Agriculture and Veterinary Medicine 27-joint-6Obihiro University of Agriculture and Veterinary Medicine 28-joint-3Obihiro University of Agriculture and Veterinary Medicine 29-joint-4
6 · The paper itself

Abstract

The emerging spread of drug-resistant malaria parasites highlights the need for new antimalarial agents. This study evaluated the growth-inhibitory effects of sparsomycin (Sm), a peptidyl transferase inhibitor, against

Indexed as

antiplasmodialPlasmodium bergheiPlasmodium falciparumPlasmodium yoeliisparsomycin

Identifiers

PMID35335918
PMCPMC8954220
OpenAlexW4214676639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.